Amid Looming Uncertainty Over EUA In US, Novavax Eyes India Launch Of Its COVID Jab With Over 90 Per Cent Efficacy
With uncertainty looming over emergency approval to its Covid-19 vaccine in the United States, the US-based Biotech firm Novavax has been eyeing other markets including India, Europe and United Kingdom to launch its jab that the company claimed has shown over 90 per cent efficacy in large phase 3 trials.
Novavax on Monday (14 June) announced that its recombinant nanoparticle protein-based COVID-19 vaccine, NVX-CoV2373, demonstrated 90.4 per cent efficacy overall in the large Phase 3 trials conducted on 29,960 persons in the US and Mexico.
Despite the efficacy of the Novavax jab being closer to Pfizer and Moderna shots and much higher than single-dose Johnson and Johnson vaccine, the firm is unlikely to get regulatory clearance soon in US as the country has already secured enough supplies for domestic use.
Under the US law, there is no need for additional emergency use authorisations (EUAs) once enough doses are secured to cater to domestic needs.
The company expects that the first approvals for its vaccine are likely to be secured from other countries' regulators and has therefore applied in India, European Union, Korea and England for regulatory nod.
In India, Novavax has partnered with Serum Institute of India, which is already manufacturing the Covishield Covid-19 vaccine presently being used in Indian vaccination drive, for the production of its jab.
The Novavax vaccine has been named Covavax in India and is in advanced stages of Phase 2 and 3 bridging trials with the Serum Institute enrolling 1,600 participants over 18 years across 15 sites, reports Economic Times.
According to the report, the government estimates availability of 20 crore Novavax shots (five crore a month) during September-December in India and the number may rise.
“The results are very encouraging and we are looking forward to the vaccine. We are already engaged with SII for supplies and the company is doing trials with ICMR. It is a very promising vaccine candidate and we are hopeful that they will be able to submit data in India for regulatory approvals very soon,” an official was quoted in the report as saying.
If the ongoing trials results are positive, India is reportedly looking at an August-September timeline for the first supplies of the Covavax, making it the first country to launch the vaccine.
Further, SII is reportedly also considering applying for expedited authorisation under the Indian government’s revised liberalised norms if Novavax secures EUA in either UK or Europe.
As you are no doubt aware, Swarajya is a media product that is directly dependent on support from its readers in the form of subscriptions. We do not have the muscle and backing of a large media conglomerate nor are we playing for the large advertisement sweep-stake.
Our business model is you and your subscription. And in challenging times like these, we need your support now more than ever.
We deliver over 10 - 15 high quality articles with expert insights and views. From 7AM in the morning to 10PM late night we operate to ensure you, the reader, get to see what is just right.
Becoming a Patron or a subscriber for as little as Rs 1200/year is the best way you can support our efforts.